RxDoctor Payments Data

Keith Carlson, MD

Ophthalmology · Burnsville, MNNPI 1679548879

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $3,214 of the $4,439 with a category attached, or 72.4%. AbbVie accounts for 72.4% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $1,121, 3.8 times the $297 reported in 2019.

$4,439in general payments, 2019–2025

Across 53 payments — averaging $83.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Alcon$789
  • Rxsight Inc$163
  • Glaukos Corporation$130
  • Johnson & Johnson Surgical Vision, Inc.$106
  • Carl Zeiss Meditec AG$19
  • plus $17 from 2 others

What the payments were for

  • Speaking & faculty fees$3,21472%
  • Travel & lodging$120%
  • Food & beverage$1,19427%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,439 in reported general payments places this provider in the 85th percentile of 330 ophthalmology providers in Minnesota.

See all ophthalmology providers in Minnesota

Medicare billing

Part B allowed, 2024
$126,717
Medicare patients
258
Services billed
1,211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine35$37,997
Prednisolone Acetate302$12,101
LumiganBimatoprost21$6,838
Travoprost27$5,682
Ketorolac Tromethamine262$4,441
Latanoprost181$3,522
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$3,478
Ofloxacin221$2,947
Brimonidine Tartrate18$2,673
Loteprednol Etabonate12$1,978
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat55$1,743
Timolol Maleate59$1,301
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha45$627
Bacitracin-PolymyxinBacitracin/Polymyxin B Sulfate12$133
Doxycycline Hyclate14$98

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$3,214$44,83556 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 330 ophthalmology providers in Minnesota.

Other ophthalmology in Burnsville

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →